https://www.selleckchem.com/pr....oducts/evobrutinib.h
38 and 4.35. Number of days of progestin per month was a significant modulator of EC risk. A decreased risk of EC was seen in obese women. Two studies documented an increased risk of EC among users of cc/scMHT with micronized progesterone. A significantly increased risk of EC among estrogen-only MHT users was demonstrated in 9/12 studies with ORs/HRs between 1.45 and 4.46. The adverse effect of estrogen-only MHT was greatest among obese women. ccMHT with SPs reduces the risk of EC, whereas estrogen-only MHT increases the risk. scMHT
Like
Comment
Share
